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Human leukocyte antigen allele (HLA)–B*5701 is associated
with abacavir hypersensitivity. However, the carriage rate of
HLA-B*5701 has rarely been studied in Asians. In 534 Korean
patients with human immunodeficiency virus infection,
HLA-B*5701 status was determined by polymerase chain re-
action with HLA-B*5701–specific primers. No patients had
the HLA-B*5701 allele (95% confidence interval, 0%–0.7%).
This explains the paucity of immunologically confirmed cases
of abacavir hypersensitivity in Koreans.
Hypersensitivity reaction is a major adverse effect of the nu-
cleoside reverse-transcriptase inhibitor abacavir, which has ac-
tivity against HIV. Because screening for HLA-B*5701 is known
to identify patients who are at risk of hypersensitivity to aba-
cavir [1, 2], recent guidelines strongly recommend screening
for HLA-B*5701 before starting patients on an abacavir-con-
taining regimen [3]. However, the carriage rate of HLA-B*5701
has rarely been studied in Asians [4], although the prevalence
of HLA-B*5701 differs in different ethnic groups [5]. We eval-
uated the frequency of the HLA-B*5701 allele and the effect of
HLA-B*5701 screening on the prevalence of abacavir hyper-
sensitivity in Korean patients with HIV infection.
Methods. In 534 Korean patients with HIV infection who
had available blood samples, the presence of HLA-B*5701 was
determined by multiplexed PCR with HLA-B*5701–specific
primers described elsewhere [6]. In brief, genomic DNA sam-
ples were extracted from whole-blood specimens with use of
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AccuPower Genomic DNA Extraction Kit (Bioneer). The se-
quence of HLA-B*5701 sequence-specific primers include
primer 1F (5′-GTCTCACATCATCCAGGT-3′), primer 2R (5′-
ATCCTTGCCGTCGTAGGCGG-3′), primer 3R (5′-ATCCTTG-
CCGTCGTAGGCAG-3′), and primer 4R (5′-CGCCTCCCACT-
TGCGCTGGG-3′). Housekeeping primer 5F HGH-I (5′-CAG-
TGCCTTCCCAACCATTCCCTTA-3′) and primer 6R HGH-II
(5′-ATCCACTCACGGATTTCTGTTGTGTTTC-3′) were also
included. DNA samples from donors who had HLA-B*5701
and HLA-B*5801 status confirmed to be positive by sequence-
based typing were used as positive and negative controls, re-
spectively. The PCR products that were amplified in touch-
down amplification-cycling conditions were electrophoresed on
a 2% agarose gel.
The prevalence of clinically suspected abacavir hypersensi-
tivity was investigated in all Korean patients with HIV infection
who received abacavir therapy at Seoul National University
Hospital (Seoul, Republic of Korea) from September 2003
through April 2008. Because the routine screening test for HLA-
B*5701 was not performed at Seoul National University Hos-
pital until October 2007, HLA-B*5701 was tested after the be-
ginning of abacavir therapy for the patients who had started
receiving abacavir before October 2007.
Clinically suspected abacavir hypersensitivity was defined as
occurrences of 2 of the following symptoms within 6 weeks
after starting abacavir treatment: fever, rash, or gastrointes-
tinal, constitutional, or respiratory symptoms that disappeared
within 3 days after discontinuing abacavir treatment and that
could not be explained by other causes. A skin patch test was
performed, as described elsewhere [7], for patients with sus-
pected cases of abacavir hypersensitivity, for which patients
provided consent. All patches were taken off after 48 h, and
reading was performed at 48 h and 72 h by 1 investigator who
was unaware of HLA-B*5701 status.
The study was approved by the Seoul National University
Hospital Institutional Review Board. Continuous variables were
compared using the Student’s t test, and categorical variables
were compared using the x2 test or Fisher’s exact test, as ap-
propriate. A P value !.05 was considered to be statistically
significant. Statistical analyses were performed with SPSS soft-
ware, version 12.0 (SPSS).
Results. Of 534 Korean patients with HIV infection for
whom the HLA-B*5701 test was performed, none had an HLA-
B*5701 allele (95% CI, 0%–0.69%). An abacavir-containing
regimen was administered to 150 patients during the study
period. Of these, 57 (38%) received abacavir without the HLA-
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Table 1. Abacavir hypersensitivity in 150 Korean patients with HIV-1 infection,








Age, median years (IQR) 45 (40–52) 41 (35–51) .144
Male sex 53 (93) 88 (95) .731
CD4 cell count, median cells/mm3 (IQR) 481 (214–710) 420 (245–602) .483
Undetectable viral load 29 (51) 50 (54) .731
Concurrent introduction
New NNRTI 5 (9) 3 (3) .260
New PI 25 (44) 16 (17) !.001
HLA-B*5701 carriera 0 (0) 0 (0) ND
Abacavir discontinuation within 6 weeks 8 (14) 7 (8) .197
Abacavir hypersensitivity reaction
Clinically suspectedb 3 (5) 4 (4) 1.999
Immunologically confirmedc 0 (0) 0 (0) ND
NOTE. Data are no. (%) of patients, unless otherwise indicated. IQR, interquartile range; ND,
not done; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
a None of 534 Korean patients with HIV infection, including these 150 patients, had HLA-B*5701.
b Occurrences of 2 of the following: fever, rash, or gastrointestinal, constitutional, or respiratory
symptoms.
c Determined by the skin patch test.
B*5701 screening test, and 93 (62%) received abacavir after the
HLA-B*5701 screening test. The HLA-B*5701 allele was not
found in any of these patients.
The median age of the 150 patients was 43 years (interquartile
range, 35–51 years); 141 (94%) were male, and 17 (11%) were
antiretroviral-naive patients. When abacavir treatment was
started, the median CD4 cell count was 441 cells/mm3 (inter-
quartile range, 236–630 cells/mm3), and 79 (53%) had unde-
tectable HIV titers. A new protease inhibitor was concurrently
introduced in treatment of 41 patients (27%), a new nonnu-
cleoside reverse-transcriptase inhibitor (NNRTI) was intro-
duced in 8 patients (5%), and neither was introduced in 101
patients (67%). There were no statistically significant differ-
ences in age, sex, CD4 cell count, HIV suppression, and the
introduction of a new NNRTI between patients who did or did
not have screening, although introduction of a new protease
inhibitor was more frequent in patients who were not screened
than in those who were screened for HLA-B*5701 (44% vs.
17%; ) (table 1).P ! .001
Fifteen patients (10%) discontinued abacavir treatment
within 6 weeks after starting therapy with the drug. Seven (5%)
of 150 patients, including 3 (5%) of 57 patients who did not
have HLA-B*5701 screening and 4 (4%) of 93 patients who
did have HLA-B*5701 screening, met the criteria for clinically
suspected abacavir hypersensitivity. There was no statistically
significant difference in the prevalence of clinically suspected
abacavir hypersensitivity between patients who had and had
not been screened for HLA-B*5701 ( ).P 1 .999
The most common symptom in 7 patients with clinically
suspected abacavir hypersensitivity was fever (6 patients
[86%]), followed by constitutional symptoms (4 [57%]), rash
(3 [43%]), gastrointestinal symptoms (3 [43%]), and respira-
tory symptoms (2 [29%]). In all cases, time to onset of symp-
toms was !21 days after initiating abacavir therapy, and there
was no patient with a severe presentation that required hos-
pitalization. The skin patch test results were all negative in 7
patients with clinically suspected abacavir hypersensitivity. The
median interval between a suspected hypersensitivity reaction
and patch test was 4 months (range, 2–48 months). There were
no cases with doubtful (i.e., faint erythema) or weak-positive
reactions.
Discussion. The present study demonstrated that HLA-
B*5701 was significantly less common (0%; 95% CI, 0%–0.7%)
in HIV-infected Koreans than in US Caucasians (6%–8%) and
African Americans (2.5%) [5]. The low frequency of HLA-
B*5701 in HIV-infected Koreans is consistent with the results
from healthy Koreans (gene frequency of HLA-B*5701, 0.2%–
0.3%) [8, 9]. The previous studies reported that East Asians,
including Taiwanese, Japanese, Chinese, and Koreans, have a
similarly low prevalence of HLA-B*5701. Sun et al. [4] reported
that only 1 (0.3%) of 320 Taiwanese patients with HIV infection
expressed HLA-B*5701, and Saito et al. [10] showed that none
of 371 Japanese expressed HLA-B*5701. The allele frequency
of HLA-B*5701 in Chinese patients was reported to be 0%–
2% in various ethnic groups [5]. It was 0.003% in Hong Kong
Chinese patients (572 patients) and 0% in Singapore Chinese
patients (149 patients) [11].
However, some Asians in selected areas other than East Asia
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showed relatively high carriage rates of HLA-B*5701. For ex-
ample, the prevalence of HLA-B*5701 is 5%–20% in selected
Asian Indian populations and 4%–10% among Thais [5].
The prevalence of suspected abacavir hypersensitivity was
9%–10% in Caucasians not routinely screened for HLA-B*5701
[1, 12]. In Korean patients with HIV infection, clinically sus-
pected abacavir hypersensitivity was relatively low (5%), even
in patients not screened for HLA-B*5701, which was com-
parable to that in Caucasians (4%) who were prospectively
screened for HLA-B*5701 [1]. In addition, because there was
no patient with a positive skin patch test result in this study,
true cases of abacavir hypersensitivity seem to be rare among
Koreans, which is compatible with a very low frequency of
HLA-B*5701 in this population [9].
HLA-B*5701 screening is supposed to be useful even in
countries with a low prevalence of HLA-B*5701, because it may
reduce clinical overdiagnosis of abacavir hypersensitivity re-
actions. However, in the present study, HLA-B*5701 screening
did not significantly decrease the prevalence of clinical diagnosis
of abacavir hypersensitivity. A negative HLA-B*5701 test result
cannot absolutely rule out abacavir hypersensitivity, because an
immunologically confirmed case of abacavir hypersensitivity in
patients without HLA-B*5701 was reported [13]. A physician
in clinical practice will decide to discontinue abacavir treatment
if hypersensitivity is clinically suspected, even for patients who
test negative for HLA-B*5701. This may be why the prevalence
of clinically suspected abacavir hypersensitivity in this study
did not decrease after HLA-B*5701 screening was introduced.
Our findings suggest that the HLA-B*5701 test may not be
cost-effective as a screening test in regions like Korea, which
has a low carriage rate of HLA-B*5701. Instead, clinical ob-
servation could replace the HLA-B*5701 screening test, es-
pecially in a resource-limited health care setting. In that case,
the skin patch test could be used to retrospectively confirm
abacavir hypersensitivity in patients who are clinically suspected
of or whose symptoms are ambiguous with regard to abacavir
hypersensitivity.
This study has some limitations. First, the patient population
may not have been large enough to determine differences in
the prevalence of abacavir hypersensitivity between patients
who did and did not undergo HLA-B*5701 screening. Second,
the concurrent introduction of other medications or medical
conditions could influence the clinical diagnosis of abacavir
hypersensitivity [1]. An NNRTI was concurrently administered
with abacavir to 5 patients (9%) who did not undergo the
HLA-B*5701 screening test and to 3 patients (3%) who did
undergo the HLA-B*5701 screening test. This infrequent use
of NNRTIs might have contributed to the low incidence of
clinically suspected hypersensitivity reaction in our study, es-
pecially NNRTI-associated skin rash.
In summary, HLA-B*5701 is very rare in Korean patients
with HIV infection, and that explains the paucity of immu-
nologically confirmed abacavir hypersensitivity in this study.
These findings suggest that the HLA-B*5701 test may be less
useful as a screening test for abacavir hypersensitivity in Asians,
who have a low prevalence of HLA-B*5701.
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